+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Hyperphosphatemia Drug"

Hyperphosphatemia Drugs - Global Strategic Business Report - Product Thumbnail Image

Hyperphosphatemia Drugs - Global Strategic Business Report

  • Report
  • April 2025
  • 390 Pages
  • Global
From
Hyperphosphatemia Treatment Market Report 2025 - Product Thumbnail Image

Hyperphosphatemia Treatment Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
From
From
From
Hyperphosphatemia - Epidemiology Forecast to 2032 - Product Thumbnail Image

Hyperphosphatemia - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Hyperphosphatemia - Pipeline Insight, 2024 - Product Thumbnail Image

Hyperphosphatemia - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 50 Pages
  • Global
From
From
From
  • 11 Results (Page 1 of 1)
Loading Indicator

The Hyperphosphatemia Drug market within the context of Hematological Drugs is a specialized market that focuses on the treatment of high levels of phosphate in the blood. Hyperphosphatemia is a condition that can be caused by a variety of medical conditions, including kidney disease, certain types of cancer, and certain medications. Treatment of hyperphosphatemia typically involves the use of drugs that bind to phosphate in the blood and prevent it from being absorbed by the body. These drugs are typically administered orally or intravenously, depending on the severity of the condition. The Hyperphosphatemia Drug market is a highly competitive market, with a number of companies offering a variety of drugs to treat the condition. Companies in the market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more